Results 101 to 110 of about 5,430 (178)

Uso del Sofosbuvir y Daclatasvir en el tratamiento de pacientes con hepatitis C / Use of Sofosbuvir and Daclatasvir in the treatment of patients with hepatitis C [PDF]

Introducción: La Infección por el virus de la hepatitis C constituye un problema sanitario a nivel mundial por su elevada incidencia. El tratamiento para esta infección experimentó un cambio en los últimos años con la comercialización de los Antivirales ...
Muñoz Castañeda, Misael Bárbaro, Díaz Elías, Javier Orlando, Fernández Sotolongo, José, Pardías Izaguirre, Yaimara, Ortiz Montero, Yosvani Josué, Arús Soler, Enrique Rogelio   +5 more
core  

Biochemical and Demographic Factors Affecting Antiviral Treatment Failure in Hepatitis C Patients with Persistent Virologic Response Issues

Pakistan Journal of Medical Research
Background: Worldwide, Hepatitis C virus (HCV) infection is a major public health concern. Twelve weeks following treatment completion, the persistent virologic response is known as SVR.
Sundus Bukhari, Mutayyaba Majeed, Maria Liaqat, Sana Shakeel, Maria Muddassir, Faheem Hadi, Tahir Maqbool   +6 more
doaj  

Anti-COVID-19 activity and simple HPLC method for concurrent detection of repurposed drugs in novel binary mixtures. [PDF]

AMB Express
Abd Elsalam MA, Kutkat O, Moatasim Y, Mostafa A, Gaballah M, Elgendy AE, Ali MA, Hadad G, Shabayek S.   +8 more
europepmc   +1 more source

Short-Term Clinical and Immunologic Outcomes Conditional on SVR12 in Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Treated With Direct-Acting Antivirals: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Boonpheng B, Ungprasert P.
europepmc   +1 more source

Stevens-Johnson syndrome associated with daclatasvir and sofosbuvir co-therapy in hepatitis C treatment: a rare case report. [PDF]

Ann Med Surg (Lond)
Sajjad W, Rehman UU, Inam A, Alam I, Ghafoor S, Razzaq HD, Khwajakhail T, Gillani SHMUD, Razzaq H, Qamar I, Ali R, Ullah Z.   +11 more
europepmc   +1 more source

A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran. [PDF]

Cost Eff Resour Alloc
Jafari M, Mehdizadeh P, Keshavarz K, Teymourzadeh E, Abyazi MA, Alavian SM, Pouria A.   +6 more
europepmc   +1 more source

STABILITY-INDICATING REVERSE-PHASE HIGH- PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD DEVELOPMENT FOR SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND DACLATASVIR IN PURE AND PHARMACEUTICAL FORMULATION

, 2019
Objective: The objective of the study was to develop a novel, simple, sensitive, accurate, precise, and stability-indicating reverse-phase (RP) liquid chromatographic method for simultaneous estimation of sofosbuvir and daclatasvir in pure and ...
RAMYA KUBER B, SWETHA A
core  

Economic evaluations of Glecaprevir/Pibrentasvir and Grazoprevir/Elbasvir for the treatment of hepatitis C: a systematic review. [PDF]

Cost Eff Resour Alloc
Jafari M, Mehdizadeh P, Teymourzadeh E, Salesi M, Keshavarz K, Abyazi MA, Heiat M, Alavian SM.   +7 more
europepmc   +1 more source

Identification of Candidate Inhibitors to SARS-CoV-2's Enzymes and Potential Disruptors of Its Structural Proteins' Interactions. [PDF]

Adv Biomed Res
Mohammadian A, Jadaliha M, Imanpour A, Pourvali Moghadam H, Jahangir A.   +4 more
europepmc   +1 more source

Safety and efficacy of different therapeutic regimens in Egyptian adults with moderate COVID-19 infection (EVEREST): a real-world retrospective study. [PDF]

Sci Rep
Abdel-Salam Elgohary M, Hamza N, Ali A, Zaher Abdel-Rahman R, Thabet Elnagar M, Emam Mohamed M, Seadawy MG, Zenhom Abdelfatah M, Taha NA, Rauof M, El-Bouseary MM.   +10 more
europepmc   +1 more source